Cargando…
A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials
Chromosome instability (CIN) in solid tumours results in multiple numerical and structural chromosomal aberrations and is associated with poor prognosis in multiple tumour types. Recent evidence demonstrated CEP17 duplication, a CIN marker, is a predictive marker of anthracycline benefit. An analysi...
Autores principales: | Spears, Melanie, Yousif, Fouad, Lyttle, Nicola, Boutros, Paul C., Munro, Alison F., Twelves, Chris, Pritchard, Kathleen I., Levine, Mark N., Shepherd, Lois, Bartlett, John MS. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741633/ https://www.ncbi.nlm.nih.gov/pubmed/26372731 |
Ejemplares similares
-
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
por: Munro, Alison F, et al.
Publicado: (2013) -
A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial
por: Spears, Melanie, et al.
Publicado: (2016) -
Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
por: Munro, A F, et al.
Publicado: (2012) -
Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer
por: Braunstein, Marsela, et al.
Publicado: (2016) -
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
por: Earl, H M, et al.
Publicado: (2012)